FindTrial
Sign In

Biomarker Data Collection

OTHER2 trials

Sponsors

GAP Innovations, PBC

Conditions

Alzheimer DiseaseAlzheimer Disease, Early OnsetAlzheimer's DiseaseAlzheimer's Disease, Early OnsetMemory DisordersMemory ImpairmentMemory LossMild Cognitive Impairment

Unknown Phase

A Biomarker Database to Investigate Blood-Based and Digital Biomarkers in Participants Screened for Alzheimer's Disease (Bio-Hermes)
CompletedNCT04733989
GAP Innovations, PBCAlzheimer Disease, Alzheimer Disease, Early Onset, Memory Disorders +3
Start: 2021-04-21End: 2022-11-11Updated: 2023-02-09
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
RecruitingNCT06584357
GAP Innovations, PBCAlzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Disorders +3
Start: 2024-09-26End: 2028-07-01Target: 1200Updated: 2026-04-15

Related Papers

Streamlining Eligibility Assessment for Alzheimers Disease-Modifying Therapies: Prediction of MMSE Scores Using the Digital Clock and Recall
2026-03-04
The Cognivue Amyloid Risk Measure (CARM): A Novel Method to Predict the Presence of Amyloid with Cognivue Clarity
Neurology and Therapy2025-04-07
Cognivue Clarity characterizes mild cognitive impairment and Alzheimer's disease in biomarker confirmed cohorts in the Bio-Hermes Study.
2024-10-187 citations
Digital Clock and Recall is superior to the Mini-Mental State Examination for the detection of mild cognitive impairment and mild dementia.
2024-01-0229 citations